Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03102736 · ClinicalTrials.gov registry record · Phase 2

Ketamine and Nitroprusside for Depression

A Phase 2 study of Depression, sponsored by Icahn School of Medicine at Mount Sinai.

Completed
Registry status
Phase 2
Development phase
40
Enrollment target
1
Study location

NCT03102736: Completed Phase 2 study of Depression, sponsored by Icahn School of Medicine at Mount Sinai.

NCT03102736 is a Phase 2 study of Depression that has completed, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 40 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03102736, a Phase 2 study of Depression, has completed, sponsored by Icahn School of Medicine at Mount Sinai.

COMPLETED
Registry status
Phase 2
Development phase
40 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to test the effects of the medication ketamine and the medication called nitroprusside in patients with major depression. Ketamine has both good and bad effects. Some studies have shown that ketamine improves depression. However, studies have also shown that it causes strange and sometimes unpleasant sensations referred to "psychotic" or "dissociative" symptoms. An example of a psychotic symptom would be hearing or seeing something that in reality is not there. The study team would like to see if nitroprusside can prevent the reported bad effects of ketamine without blocking the reported good effects. This might make ketamine a better treatment for depression.

Primary Outcome

This is a 10-item instrument used for the evaluation of depressive symptoms in adults and for the assessment of any changes to those symptoms. Each of the 10 items is rated on a scale of 0 to 6, with differing descriptors for each item. These individual item scores are added together to form a total score, which can range between 0 (normal) and 60 (severe depression).

Conditions Studied

Interventions

  • DRUG Ketamine
  • DRUG Placebos
  • DRUG Nitroprusside

Study Locations (1)

New York

  • Icahn School of Medicine at Mount Sinai - New York

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2017-02-14
Est. Completion 2019-06-12
Phase Phase 2

What the finished NCT03102736 record still lists

NCT03102736 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 786-participant average among 679 other Depression trials with a reported enrollment target (95% lower).

The record links to 1 condition, with Depression appearing as the primary indexed condition, and to 3 interventions - of which Ketamine is the first listed.

NCT03102736 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT03102736 about?

NCT03102736 is a clinical study titled "Ketamine and Nitroprusside for Depression". The purpose of this study is to test the effects of the medication ketamine and the medication called nitroprusside in patients with major depression. Ketamine has both good and bad effects. Some studies have shown that ketamine improves depression. However, studies have also shown that it causes st...

What is the current status of trial NCT03102736?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2017-02-14. Estimated completion is 2019-06-12.

What conditions does trial NCT03102736 study?

This clinical trial studies the following conditions: Depression.

What interventions are being tested in trial NCT03102736?

The interventions under investigation include: Ketamine (DRUG), Placebos (DRUG), Nitroprusside (DRUG).

Who is sponsoring clinical trial NCT03102736?

This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03102736 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Depression

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03102736's enrollment target sits among peer trials

40 509th of 679 higher than 151 of 679 other Depression trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Depression trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01306019 · 40 participants · Phase 1

    Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)

  • NCT01608152 · 40 participants

    Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors

  • NCT01668082 · 40 participants · NA

    An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection

  • NCT02015013 · 40 participants · Phase 2

    Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT06358040 · started 2026-10 · NA

    Opioid Dispenser for Microdiscectomy/Laminectomy

Source: ClinicalTrials.gov NCT03102736, the US trial registry maintained by the National Library of Medicine. NCT03102736 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.